HCW Biologics (HCWB) Expected to Release Earnings on Friday

by · The Cerbat Gem

HCW Biologics (NASDAQ:HCWB – Get Free Report) is expected to announce its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect HCW Biologics to announce earnings of ($1.98) per share and revenue of $5.7270 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

HCW Biologics (NASDAQ:HCWB – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of ($2.64) by $3.01. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%. The firm had revenue of $6.54 million for the quarter, compared to analyst estimates of $6.54 million.

HCW Biologics Price Performance

Shares of HCW Biologics stock opened at $3.43 on Thursday. The business has a 50 day simple moving average of $5.81 and a two-hundred day simple moving average of $5.11. HCW Biologics has a 12 month low of $1.50 and a 12 month high of $44.10. The stock has a market capitalization of $5.49 million, a P/E ratio of -0.06 and a beta of 2.32.

Analysts Set New Price Targets

HCWB has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. Maxim Group increased their price objective on HCW Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Finally, Wall Street Zen upgraded HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, HCW Biologics has an average rating of “Hold” and an average target price of $30.00.

View Our Latest Research Report on HCW Biologics

Insider Buying and Selling

In other HCW Biologics news, Director Scott T. Garrett bought 29,656 shares of HCW Biologics stock in a transaction on Friday, May 22nd. The shares were bought at an average price of $8.46 per share, for a total transaction of $250,889.76. Following the completion of the transaction, the director directly owned 33,906 shares of the company’s stock, valued at $286,844.76. This trade represents a 697.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders acquired a total of 47,500 shares of company stock valued at $310,875 in the last quarter. 9.10% of the stock is owned by insiders.

Hedge Funds Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics at the end of the most recent reporting period. 2.96% of the stock is currently owned by institutional investors and hedge funds.

About HCW Biologics

(Get Free Report)

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.

Featured Stories